배란 테스트 키트 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of ovulation testing kits Market

The global ovulation testing kits market size was valued at USD 266.4 million in 2025 and is projected to grow from USD 282.9 million in 2026 to USD 489.7 million by 2034, exhibiting a CAGR of 7.10% during the forecast period (2026-2034). North America dominated the market with a 74.20% share in 2025, primarily due to the high prevalence of Polycystic Ovary Syndrome (PCOS), strong awareness regarding fertility health, and widespread adoption of at-home testing solutions.

Ovulation testing kits are diagnostic tools designed to help women track their menstrual cycle and determine their fertility window. These kits typically detect luteinizing hormone (LH) surge or progesterone metabolites, helping women plan pregnancy more effectively. They are widely used among women experiencing irregular ovulation, particularly those suffering from PCOS.

COVID-19 IMPACT

During the COVID-19 outbreak in 2020, the market experienced slow growth due to supply chain disruptions, limited product availability, and reduced visits to gynecologists. However, in the second half of 2020, demand rebounded significantly as consumers increasingly preferred home-based fertility monitoring solutions. This shift toward self-testing and telehealth-supported diagnostics positively influenced long-term market growth.

MARKET TRENDS

Increasing Focus on New Product Launches and Collaborations

Growing awareness regarding PCOS and fertility tracking has encouraged companies to introduce innovative products. Market players are increasingly launching digital and app-connected ovulation kits that offer accurate, quick, and easy-to-interpret results.

For instance, in May 2023, Fridababy, LLC launched a new line of fertility products, including an ovulation prediction test and ovulation & pregnancy tracking kits. Similarly, in July 2023, Proov collaborated with Quest Diagnostics Incorporated to expand access to Confirm PdG, an at-home fertility testing kit. Such initiatives are enhancing product availability and boosting global adoption.

MARKET GROWTH FACTORS

Increasing Prevalence of PCOS

Polycystic Ovary Syndrome (PCOS) is a leading hormonal disorder affecting reproductive-aged women, often causing irregular menstrual cycles and infertility. According to the World Health Organization (WHO) (June 2023), PCOS affects approximately 8-13% of women globally and is one of the leading causes of infertility.

In India, as per the National Center for Biotechnology Information (NCBI) (2022), the prevalence of PCOS was around 10% among women aged 15-45 years as per the Androgen Excess Society (AES), and 5.8% as per the National Institutes of Health (NIH). This rising prevalence is significantly driving demand for ovulation testing kits.

Additionally, ovulation kits offer high accuracy levels. According to Cloudnine Fertility (November 2022), ovulation prediction kits can be around 97% accurate, which further supports their adoption.

RESTRAINING FACTORS

Clinical Limitations and Risk of False Results

Despite their benefits, ovulation testing kits have certain limitations. According to an article published by Dotdash Meredith (June 2023), ovulation tests may provide inaccurate results when used alongside medications such as hormonal birth control, fertility drugs, or antibiotics containing tetracycline.

Moreover, while ovulation kits can detect LH surge with up to 99% effectiveness, they cannot confirm ovulation or guarantee pregnancy. Since these kits only track ovulation and not egg viability, their limitations may hinder broader adoption.

MARKET SEGMENTATION ANALYSIS

By Device Type

The market is segmented into digital devices, line indicator devices, and microscopic devices.

• The digital devices segment is projected to hold 89.57% market share in 2026, driven by higher accuracy, faster results, reliability, and ease of use.
• The line indicator devices segment is expected to record the fastest CAGR due to affordability and convenience for home use.
• The microscopic devices segment is anticipated to grow steadily owing to reusability and long-term usability.

By Sample Type

Based on sample type, the market is segmented into blood, urine, and saliva.

• The blood segment is expected to dominate with 89.15% share in 2026, attributed to higher accuracy and integration with mobile applications for result tracking.
• The urine segment is anticipated to grow significantly due to increased product launches, such as Ro's urine-based LH detection kit launched in June 2020.

By End-User

The market is segmented into fertility centers, hospitals & clinics, and others.

• The fertility centers segment is projected to lead with 57.72% share in 2026, supported by the rising number of fertility clinics globally.
• The hospitals & clinics segment is expected to grow at a significant rate due to increasing patient preference for combined testing and treatment facilities.

REGIONAL INSIGHTS

North America

North America accounted for the largest market share in 2025 (74.20%). The regional market is estimated to reach USD 210.4 million in 2026, driven by high PCOS prevalence and strong awareness of fertility testing.

Europe

Europe holds a substantial market share due to the presence of key players such as Geratherm Medical AG and SPD Swiss Precision Diagnostics GmbH. The region benefits from advanced healthcare infrastructure and fertility treatment adoption.

Asia Pacific

Asia Pacific is projected to witness significant growth during the forecast period due to rising infertility cases in China and India, increasing awareness, and expanding access to digital health solutions.

Rest of the World

The market in other regions is expected to grow steadily due to the increasing penetration of global manufacturers into untapped markets.

KEY INDUSTRY PLAYERS

Major companies operating in the market include:

• Piramal Pharma Ltd.
• Geratherm Medical AG
• SPD Swiss Precision Diagnostics GmbH
• The Boots Company PLC
• Proov
• Ro
• Wondfo
• Everly Health, Inc.
• Alfa Scientific Designs, Inc.
• AdvaCare Pharma

These companies focus on mergers, acquisitions, partnerships, and product innovation to strengthen their market presence.

KEY INDUSTRY DEVELOPMENTS

• July 2023: Proov signed a distribution agreement with 2SAN GLOBAL LIMITED to expand product distribution in the U.S.
• May 2023: Fridababy launched new fertility product lines.
• January 2022: Kindbody launched "Kind at Home" fertility test kits.
• May 2021: Ro acquired Modern Fertility to expand fertility product offerings.

CONCLUSION

The global ovulation testing kits market is expected to grow from USD 266.4 million in 2025 to USD 489.7 million by 2034, rising at a CAGR of 7.10%. The market will expand to USD 282.9 million in 2026, driven by increasing PCOS prevalence, rising awareness about fertility health, and strong demand for home-based digital testing solutions. While limitations related to accuracy and medication interference remain challenges, ongoing product innovations, digital integration, and expanding fertility clinics are expected to sustain long-term market growth through 2034.

Segmentation By Device Type

• Line Indicator Devices
• Digital Devices
• Microscopic Devices

By Sample Type

• Urine
• Blood
• Saliva

By End-User

• Hospitals & Clinics
• Fertility Centers
• Others

By Region

• North America (By Device Type, Sample Type, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Device Type, Sample Type, End-user, and Country)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Device Type, Sample Type, End-user, and Country)
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia Pacific
• Rest of the World (By Product, Sample Type, and End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Infertility Among Women - by Key Countries/Sub-region, 2025
• 4.2. New Product Launches
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.4. Impact of COVID-19 on the Market

5. Global Ovulation Testing Kits Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Device Type
  • 5.1.1. Line Indicator Devices
  • 5.1.2. Digital Devices
  • 5.1.3. Microscopic Devices
• 5.2. Market Analysis, Insights and Forecast - By Sample Type
  • 5.2.1. Urine
  • 5.2.2. Blood
  • 5.2.3. Saliva
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Fertility Centers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Ovulation Testing Kits Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Device Type
  • 6.1.1. Line Indicator Devices
  • 6.1.2. Digital Devices
  • 6.1.3. Microscopic Devices
• 6.2. Market Analysis, Insights and Forecast - By Sample Type
  • 6.2.1. Urine
  • 6.2.2. Blood
  • 6.2.3. Saliva
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Fertility Centers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Ovulation Testing Kits Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Device Type
  • 7.1.1. Line Indicator Devices
  • 7.1.2. Digital Devices
  • 7.1.3. Microscopic Devices
• 7.2. Market Analysis, Insights and Forecast - By Sample Type
  • 7.2.1. Urine
  • 7.2.2. Blood
  • 7.2.3. Saliva
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Fertility Centers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Rest of the Europe

8. Asia Pacific Ovulation Testing Kits Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Device Type
  • 8.1.1. Line Indicator Devices
  • 8.1.2. Digital Devices
  • 8.1.3. Microscopic Devices
• 8.2. Market Analysis, Insights and Forecast - By Sample Type
  • 8.2.1. Urine
  • 8.2.2. Blood
  • 8.2.3. Saliva
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Fertility Centers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Rest of Asia Pacific

9. Rest of the World Ovulation Testing Kits Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Device Type
  • 9.1.1. Line Indicator Devices
  • 9.1.2. Digital Devices
  • 9.1.3. Microscopic Devices
• 9.2. Market Analysis, Insights and Forecast - By Sample Type
  • 9.2.1. Urine
  • 9.2.2. Blood
  • 9.2.3. Saliva
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Fertility Centers
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Piramal Pharma Ltd.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Geratherm Medical AG
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. SPD Swiss Precision Diagnostics GmbH
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. The Boots Company PLC
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Alfa Scientific Designs, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Proov
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Ro Wondfo
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. AdvaCare Pharma
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Everly Health, Inc.
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)